This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ray, D. Articles by Kiyokawa, H. Search for Related Content PubMed PubMed Citation Articles by Ray, D. Articles by Kiyokawa, H.

Hemizygous Disruption of Cdc25A Inhibits Cellular Transformation and Mammary Tumorigenesis in Mice

¹ Department of Molecular Pharmacology and Biological Chemistry and ² Robert H. Lurie Comprehensive Cancer Center, Northwestern University, and ³ Department of Biochemistry and Molecular Genetics, ⁴ Research Resources Center, and ⁵ Department of Surgical Oncology, University of Illinois College of Medicine, Chicago, Illinois

Requests for reprints: Hiroaki Kiyokawa, Department of Molecular Pharmacology & Biological Chemistry, Northwestern University, 303 E. Superior Street, Lurie 3-113, Chicago, IL 60611. Phone: 312-503-0699; Fax: 312-503-0700; E-mail: kiyokawa{at}northwestern.edu.

CDC25A phosphatase activates multiple cyclin-dependent kinases (CDK) during cell cycle progression. Inactivation of CDC25A by ubiquitin-mediated degradation is a major mechanism of DNA damage-induced S-G₂ checkpoint. Although increased CDC25A expression has been reported in various human cancer tissues, it remains unclear whether CDC25A activation is a critical rate-limiting step of carcinogenesis. To assess the role for CDC25A in cell cycle control and carcinogenesis, we used a Cdc25A-null mouse strain we recently generated. Whereas Cdc25A^–/– mice exhibit early embryonic lethality, Cdc25A^+/– mice show no appreciable developmental defect. Cdc25A^+/– mouse embryonic fibroblasts (MEF) exhibit normal kinetics of cell cycle progression at early passages, modestly enhanced G₂ checkpoint response to DNA damage, and shortened proliferative life span, compared with wild-type MEFs. Importantly, Cdc25A^+/– MEFs are significantly resistant to malignant transformation induced by coexpression of H-ras^V12 and a dominant negative p53 mutant. The rate-limiting role for CDC25A in transformation is further supported by decreased transformation efficiency in MCF-10A human mammary epithelial cells stably expressing CDC25A small interfering RNA. Consistently, Cdc25A^+/– mice show substantially prolonged latency in mammary tumorigenesis induced by MMTV-H-ras or MMTV-neu transgene, whereas MMTV-myc–induced tumorigenesis is not significantly affected by Cdc25A heterozygosity. Mammary tissues of Cdc25A^+/–;MMTV-neu mice before tumor development display less proliferative response to the oncogene with increased tyrosine phosphorylation of CDK1/2, but show no significant change in apoptosis. These results suggest that Cdc25A plays a rate-limiting role in transformation and tumor initiation mediated by ras activation. [Cancer Res 2007;67(14):6605–11]

This article has been cited by other articles:

				D. Zheng, Y.-Y. Cho, A. T.Y. Lau, J. Zhang, W.-Y. Ma, A. M. Bode, and Z. Dong Cyclin-Dependent Kinase 3-Mediated Activating Transcription Factor 1 Phosphorylation Enhances Cell Transformation Cancer Res., September 15, 2008; 68(18): 7650 - 7660. [Abstract] [Full Text] [PDF]

				J. Jin, X. L. Ang, X. Ye, M. Livingstone, and J. W. Harper Differential Roles for Checkpoint Kinases in DNA Damage-dependent Degradation of the Cdc25A Protein Phosphatase J. Biol. Chem., July 11, 2008; 283(28): 19322 - 19328. [Abstract] [Full Text] [PDF]

				D. Ray and H. Kiyokawa CDC25A Phosphatase: a Rate-Limiting Oncogene That Determines Genomic Stability Cancer Res., March 1, 2008; 68(5): 1251 - 1253. [Abstract] [Full Text] [PDF]